United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $6.19, $0.49 worse than the analyst estimate of $6.68. Revenue for the quarter came in at $735.9 million versus the consensus estimate of $739.92 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.